{"entity":{"id":"nct07328217","kind":"trial","name":"A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of GW5282 in advanced solid tumours, run by Dizal Pharmaceuticals, now recruiting.","summary":"A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07328217 by Dizal Pharmaceuticals, with 203 participants planned, started 2026-01-29 and due to reach its primary completion in 2028-12. Interventions recorded: GW5282.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07328217","url":"https://clinicaltrials.gov/study/NCT07328217"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["dizal"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07328217","phase":"1/2","setting":"A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Efficacy of GW5282 in Participants With Advanced Solid Tumors (BEI-DOU2)","sponsor":"Dizal Pharmaceuticals","enrolled":203,"outcomes":[]},"route":"/trials/nct07328217/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","route":"/companies/dizal/"}]}}